Aurinia Pharmaceuticals (AUPH) Lifted Revenue Guidance, Is The Stock Still A Bargain?

Aurinia Pharmaceuticals (AUPH) drew fresh attention on 30 October 2026 after reporting third quarter results alongside higher full year revenue guidance, tying current performance directly to management’s outlook.

Despite a softer reaction on the day, with a 1-day share price return that fell 3.25% to US$16.65, Aurinia Pharmaceuticals has logged a 30-day share price return of 2.81% and a 90-day move of 11.90%. The 1-year total shareholder return of 26.42% and 3-year total shareholder return of 102.31% point to momentum that has been building over a multi year horizon, even as the 5-year total shareholder return remains down 47.94%.

Scan for other biopharma stories with similar earnings catalysts by reviewing our curated 18 high quality undiscovered gems that are starting to attract fresh attention from the market.

Bulls point to Aurinia Pharmaceuticals’ profitable lupus nephritis franchise and higher 2026 revenue guidance, while bears see a 5 year return still deeply in the red. Which case does the current valuation lean toward?

Most Popular Narrative: 8% Undervalued

Aurinia Pharmaceuticals is framed as modestly undervalued in the most followed narrative, with a fair value of $18.17 against the recent $16.65 close. That gap hinges heavily on how durable LUPKYNIS proves to be as a cash generator and how much credit investors give to the early stage pipeline.

A biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs.

See why 17 investors see Aurinia Pharmaceuticals as 8% undervalued.

Result: Fair Value of $18.17 (UNDERVALUED)

Still, the Aurinia Pharmaceuticals story leans heavily on a single drug and faces ongoing pricing and reimbursement pressure, which could quickly challenge this underpricing thesis.

Find out about the key risks to this Aurinia Pharmaceuticals narrative.

Next Steps

Does the split sentiment around Aurinia Pharmaceuticals make sense to you, or does the data point somewhere else entirely? Act quickly, review both sides of the story, and pressure test your own thesis starting with 3 key rewards and 3 important warning signs

Ready for more ideas beyond Aurinia Pharmaceuticals?

If Aurinia Pharmaceuticals has sharpened your thinking, do not stop here. Use powerful screeners to quickly surface other opportunities that fit your style.

• Target resilience by focusing on balance sheets that can handle shocks through a curated list of solid balance sheet and fundamentals (25 results).
• Hunt for mispriced opportunities where quality and valuation line up using the 29 high quality undervalued stocks.
• Prioritise stability and income potential by scanning companies in the 5 dividend fortresses before yields move away from you.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com